SILO Pharma (SILO Pharma) 3-Year Revenue Growth Rate : 0.00% (As of Mar. 2024)

View and export this data going back to 2012. Start your Free Trial

What is SILO Pharma 3-Year Revenue Growth Rate?

SILO Pharma's Revenue per Share for the three months ended in Mar. 2024 was $0.01.

During the past 12 months, SILO Pharma's average Revenue per Share Growth Rate was -20.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of SILO Pharma was -28.40% per year. The lowest was -28.40% per year. And the median was -28.40% per year.

Competitive Comparison of SILO Pharma's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, SILO Pharma's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SILO Pharma's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SILO Pharma's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where SILO Pharma's 3-Year Revenue Growth Rate falls into.

SILO Pharma 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

SILO Pharma (NAS:SILO) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

SILO Pharma 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of SILO Pharma's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

SILO Pharma (SILO Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SILO Pharma Inc (NAS:SILO) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

560 Sylvan Avenue, Suite 3160, Englewood Cliffs, NJ, USA, 07632

Website

https://www.silopharma.com

SILO Pharma Inc is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. The company is engaged in developing innovative solutions to address a variety of underserved conditions which includes Alzheimer's; Parkinson's; Multiple Sclerosis (MS); Rheumatoid Arthritis (RA); and Stress-Induced Psychiatric Disorders.

Executives

Eric Weisblum	director, officer: President and CCO	285 GRAND AVENUE, ENGLEWOOD NJ 07631
Daniel E. Ryweck	officer: Chief Financial Officer	712 VISTA BLVD #305, WACONIA MN 55387
Jeff Pavell	director	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Kevin Munoz	director	560 SYLVAN AVE, SUITE 3160, ENGLEWOOD CLIFF NJ 07632
Wayne Linsley	director	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Adam C Wasserman	officer: Chief Financial Officer	1643 ROYAL GROVE WAY, WESTON FL 33327
Leonard M Schiller	director
Joel Alan Stone,	director	1772 SABAL PALM DR., BOCA RATON FL 33432
Parker Walter Van Eps	director	C/O PROSPECT ENERGY CORPORATION, 10 E. 40TH STREET, 44TH FLOOR, NEW YORK NY 10016
Richard Brand	director, officer: Chairman and CEO	10 E. 40TH STREET, 44TH FLOOR, NEW YORK NY 10016
Whalehaven Capital Fund Ltd	10 percent owner	P O BOX HM 1027, HAMILTON D0 HMDX
Vadim Mats	officer: VP of Business Development	285 GRAND AVENUE, ENGLEWOOD NJ 07631
Donald Ptalis	director, officer: CFO	72 POND ROAD, WOODBURY NY 11797
Melvin Schlossberg	director, 10 percent owner, officer: PRESIDENT, CEO & SECRETARY	72 POND ROAD, WOODBURY NY 11797